The procedural success rates were 80.8% and 75.4% for the PCB and PTA groups, respectively (P ‫؍‬ .24). With use of the PCB, the primary patency rates of the target lesions were 84.3%, 65.8%, and 47.9% at 1 month, 3 months, and 6 months, respectively. With PTA, the primary patency rates of the target lesions were 77.7%, 63.4%, and 40.5% at 1 month, 3 months, and 6 months, respectively. The primary patency rates of the entire vascular access circuit were 82.6%, 61.0%, and 43.3% at 1 month, 3 months, and 6 months, respectively, with use of the PCB. For patients who were treated with PTA, the primary patency rates of the vascular access circuit were 75.9%, 61.0%, and 36.3% at 1 month, 3 months, and 6 months, respectively. When comparing the PCB and PTA, there was no difference in the 6-month primary patency rates in the target lesion (P ‫؍‬ .373) or the entire vascular access circuit (P ‫؍‬ .531). There were nine device-related complications in the PCB group (5.2%): five venous ruptures (2.9%), three venous dissections (1.7%), and one case of thrombosis (0.6%). There were no device-related complications in the PTA group.
THE natural history of a polytetrafluoroethylene (PTFE) hemodialysis graft is the gradual development of neointimal hyperplastic stenoses. Although these lesions most commonly occur at the venous anastomosis, they can be found anywhere along the venous outflow tract (1) . The characteristic neointimal hyperplastic stenosis is a concentric, focal thickening of the vascular wall consisting of smooth muscle cells and extracellular matrix (2) . The progression of a neointimal hyperplastic stenosis creates a focal narrowing in the graft or native vein, which reduces blood flow and thereby decreases the performance of the vascular access. If left untreated, a venous anastomotic stenosis will eventually lead to thrombosis of the hemodialysis graft.
Balloon angioplasty is the primary endovascular technique for treatment of vascular access-related stenoses. The neointimal hyperplastic stenoses associated with hemodialysis grafts are more difficult to dilate and tend to recur rapidly compared with arterial atherosclerotic lesions (3) . The use of high-pressure (Ͼ20 atm) and ultrahigh-pressure (Ͼ30 atm) angioplasty balloons has improved our ability to successfully dilate vascular access-related stenoses (4, 5) . However, despite these improvements in angioplasty balloon technology, the long-term results of angioplasty remain dismal.
Balloon angioplasty of a stenosis is a traumatic event that damages the vascular wall and incites a reparative process, the development of neointimal hyperplasia at the site of vascular injury. A new type of angioplasty balloon, the peripheral cutting balloon (PCB), creates microsurgical incisions in the vascular wall, which facilitates dilation of hemodialysis-related steno-ses. With use of this device, a stenosis can be effectively dilated with the least amount of radial force, thereby reducing trauma to the vessel wall. By using low-pressure dilation and minimizing vascular injury, the PCB may provide more long-lasting treatment of vascular access-related stenoses.
This prospective study was performed to compare the efficacy and safety of the use of the PCB versus conventional percutaneous transluminal angioplasty (PTA) for the treatment of hemodialysis-related stenoses.
MATERIALS AND METHODS
This clinical trial was performed at 27 medical centers in the United States (Appendix 1). The investigational protocol was approved by the institutional review board at each medical center before patient enrollment. Informed consent was obtained after the nature of the procedure was described to each patient. This study was funded by Boston Scientific Corporation, Natick, MA.
Study Design
This prospective, randomized clinical trial was performed to compare the safety and efficacy of the use of the PCB versus conventional PTA for the treatment of hemodialysis graft-related venous stenoses. The study patient population consisted of two groups: (i) patients with dysfunctional, stenotic hemodialysis grafts and (ii) patients with thrombosed hemodialysis grafts. Within each group, the patients were randomized to receive PTA or treatment with the PCB. The patients were followed for 6 months to determine the efficacy of the two treatment methods.
Enrollment Criteria
Patients receiving chronic hemodialysis treatment for dysfunctional or thrombosed PTFE hemodialysis grafts were eligible for enrollment. Informed consent was obtained from each patient before enrollment.
There were two categories of inclusion and exclusion criteria: clinical criteria and angiographic criteria. The clinical inclusion and exclusion criteria are presented in Table 1 . The clinical and hemodynamic criteria that defined a dysfunctional hemodialysis graft were obtained from Guideline 19 of the National Kidney Foundation's Dialysis Outcomes Quality Initiative Clinical Practice Guidelines for Vascular Access (6) . These criteria included increased recirculation values, increased venous pressures, decreased intragraft blood flow, and abnormal physical findings.
If at least one of the clinical criteria were satisfied, the patient was brought The patient has a synthetic hemodialysis graft located in the forearm or upper arm, and has alternative access sites available The hemodialysis graft is Ͼ 3 months old The patient has clinical or hemodynamic evidence of graft dysfunction, or the hemodialysis graft is thrombosed The patient is Ն 18 years of age The patient understands the study requirements and is willing to comply with follow-up evaluations; patient is willing to provide informed consent
Clinical Exclusion Criteria
The patient has had any intervention of the vascular access circuit within the past 30 days The patient has an existing stent within the vascular access circuit Evidence of systemic infection or a local infection associated with the graft Positive pregnancy test within 7 days before enrollment Patient is scheduled for a kidney transplant Patient is enrolled in another investigational study Patient has comorbid conditions that may limit their ability to comply with the follow-up requirements Life expectancy Ͻ6 months Documented allergy to heparin or radiographic contrast material Table 2 Angiographic Criteria for Patient Enrollment
Angiographic Inclusion Criteria
The patient has a stenosis (target lesion) causing Ͼ50% luminal reduction when compared to the reference vessel diameter The target lesion is located Յ3.0 cm from the venous anastomosis The target lesion is Յ3.0 cm in length The patient may have a maximum of two secondary lesions (stenoses) if the following criteria are satisfied: The secondary lesion is located in the graft or peripheral veins The secondary lesion is Յ5.0 cm in length The secondary lesion is located Ͼ1.0 cm away from the target lesion The secondary lesion causes Ͼ50% luminal reduction compared to the reference vessel diameter The secondary lesions are treated first, before randomization, using a conventional angioplasty balloon Treatment of the secondary lesion(s) is successful with Ͻ30% residual stenosis and no complications
Angiographic Exclusion Criteria
The target lesion segment has an angulation Ͼ45°with respect to the adjacent vein or graft The reference vessel has a diameter Ͼ8 mm The patient has a significant (Ͼ50%) central venous stenosis The patient has a pseudoaneurysm adjacent to the target lesion In the opinion of the operating physician, the hemodialysis graft is unsuitable for endovascular treatment into the angiography suite and a diagnostic fistulogram was obtained to verify the presence of a stenosis (ie, target lesion) that met the angiographic inclusion criteria. The graft and native veins were also evaluated to identify secondary stenoses that affected patient enrollment. The angiographic inclusion and exclusion criteria are presented in Table 2 .
Assessment of Stenoses
Diagnostic fistulography and a thorough evaluation of the native outflow veins was performed to identify and evaluate the target lesion and any secondary stenoses. All lesions were characterized by location, length, and degree of stenosis. Patients presenting with thrombosed hemodialysis grafts also underwent diagnostic angiography to identify and characterize significant stenoses. The angiographic criteria were assessed and satisfied before any treatment was performed.
The target lesion and secondary stenoses were imaged in two orthogonal planes. The imaging plane that demonstrated the greatest degree of stenosis was used for subsequent anatomic measurements. Anatomic measurements were made with use of a calibrated reference marker or the computer-assisted edge detection software within the angiographic imaging system. The reference vessel was defined as an adjacent segment of normal vein located upstream from the target lesion. If a normal segment of vein could not be identified, the investigator was allowed to use an adjacent segment of normal graft as an alternative reference vessel. The degree of stenosis was reported as the maximum diameter reduction compared with the reference vessel diameter ( Table 3) . If the reference vessel was greater than 8 mm in diameter, the patient was excluded from the study.
As defined by the angiographic inclusion criteria, the target lesion was a juxtaanastomotic stenosis located no more than 3.0 cm from the venous anastomosis of the PTFE graft, was no more than 3.0 cm in length, and had less than 45°angulation with the adjacent graft or native vein.
Patients with no more than two additional stenoses were admitted into the study. However, these lesions must have also satisfied the anatomic criteria for secondary stenoses ( Table  2) . Secondary stenoses were treated with conventional PTA before patient enrollment and randomization. This treatment had to be successful with less than 30% residual stenosis and no complications. The number and location of secondary lesions treated are described in Table 4 .
As previously described, the anatomic characteristics of the target lesion were measured and recorded before treatment. Patients who satisfied all angiographic criteria were randomized to receive conventional PTA or treatment with the PCB.
Randomization
Consenting subjects who satisfied the clinical and angiographic criteria for enrollment were stratified with respect to their clinical presentation: (i) patients with a patent but dysfunctional graft and (ii) patients with a thrombosed graft.
Each study center received two sets of secure envelopes labeled sequentially: one set for patients with dysfunctional grafts and one set for patients with thrombosed grafts. Randomization schedules were computergenerated so patients within each subgroup at each clinical site were randomized in a 1:1 ratio to undergo conventional PTA or PCB treatment. Enrollment occurred after confirmation of all inclusion and exclusion criteria and the randomization envelope was opened.
Patient Demographics
Between July 2002 and April 2003, a total of 340 patients were enrolled at 27 medical centers in the United States. The subgroup stratification of these patients is shown in Figure 1 . There were 195 patients who presented with dysfunctional stenotic hemodialysis grafts and 145 patients who presented with thrombosed grafts. The randomization process yielded 173 patients in the PCB group and 167 patients in the conventional PTA group.
The demographic characteristics of the patient population are presented in Table 5 . There were no significant differences in the demographic characteristics of the two treatment groups.
The characteristics of the hemodialysis grafts are presented in Table 6 . The only variable that was statistically different between the two treatment groups was graft location (P ϭ .017). However, when adjusted for this variable, graft location did not significantly alter the treatment affect on the primary endpoint. 
Procedure
Conventional PTA.-For patients with dysfunctional but patent hemodialysis grafts who were randomized to receive conventional PTA, the investigator physician was allowed to use any type and any size of commercially available angioplasty balloon. The physician was allowed to use an "oversized" balloon to treat the stenosis if so desired. The most common (48.8%) diameter of conventional angioplasty balloon was 7 mm ( Table 7) . The mean (ϮSD) length of the conventional angioplasty balloons was 4.0 cm Ϯ 1.1 (range, 1.0 -10.0 cm).
An appropriately sized introducer sheath was inserted into the PTFE graft. The use of heparin was allowed and left to the discretion of the individual physician. After crossing the stenosis with a guide wire, the angioplasty balloon was appropriately positioned across the target lesion under fluoroscopic guidance. With use of an inflation device with a pressure gauge, the balloon was slowly inflated with a 1:1 mixture of radiographic contrast agent and saline solution. The mean number of inflations per balloon was 1.8 Ϯ 0.8 (range, 1-5 inflations). The mean maximum pressure used to inflate the conventional angioplasty balloons was 15.7 atm Ϯ 4.9 (range, 6.0 -30.0 atm). The duration of balloon inflation was determined by the physician investigator. If necessary, the balloon could be deflated, repositioned, and reinflated to treat longer lesions. At the end of the procedure, a final fistulogram was obtained.
PCB Treatment.-The PCB is designed to minimize the vascular trauma that is associated with conventional angioplasty. Inflation of the PCB creates microsurgical incisions in the vein wall, which facilitates dilation with the least amount of radial expansion force.
The PCB consists of a noncompliant balloon with four atherotomes mounted longitudinally on its outer surface (Fig 2) . The atherotomes have a working height of 0.127 mm (0.007 inches) and are 1.0 cm in length. Radiopaque markers, 0.035 inches in width, are fixed onto the catheter to delineate the ends of the atherotomes and to provide a visual reference for positioning the balloon within the lesion. The PCB catheter is 50 cm in length and has two lumens. The inner guide wire lumen accepts a 0.018-inch guide wire. The outer lumen is used for inflation of the balloon. This device is compatible with a 7-F introducer sheath. At the time of this clinical trial, the PCB was an investigational device.
The investigating physician selected the most appropriate device based on the diameter of the vessels adjacent to the target lesion. The diameters of PCBs used included 5.0 mm, 5.5 mm, 6.0 mm, 7.0 mm, and 8.0 mm. Oversizing the balloon diameter may increase the risk of vessel perforation. Therefore, the diameter of the PCB was restricted so it did not exceed a ratio of 1.1:1 (balloon to reference vessel diameter). The most common (47.6%) diameter used in this clinical trial was 6 mm ( Table 7) .
With use of an 0.018-inch guide wire, the PCB was advanced through a 7-F sheath and appropriately positioned across the target lesion under fluoroscopic guidance. The use of heparin was allowed and left to the discretion of the individual physician. An inflation device with a pressure gauge was used to slowly inflate the balloon with a 1:1 mixture of contrast medium and saline solution. The manufacturer's recommended rate for inflation of the PCB is 1 atm pressure in 5 seconds. The nominal inflation pressure of the PCB is 6 atm and the rated burst pressure is 10 atm. The mean maximum pressure used to inflate the PCBs was 8.1 atm Ϯ 1.7 (range, 4.0 -14.0 atm). The duration of balloon inflation was determined by the physician investigator. At the time of this clinical trial, the PCB was only available in one length, 1 cm. Therefore, treatment of longer lesions required repositioning of the balloon and multiple inflations. The mean number of inflations of the PCB was 3.3 Ϯ 1.9 (range, 1-10 inflations). At the end of the procedure, a final fistulogram was obtained. 
Thrombosed Hemodialysis Grafts
The 145 patients who presented with thrombosed hemodialysis grafts underwent identical treatment of the target lesion. A graft thrombectomy procedure was performed before treatment of the target lesion. However, the physician investigator was required to measure and document the anatomic characteristics of the target lesion and any secondary lesions before the thrombectomy procedure. The angiographic inclusion criteria had to be assessed and satisfied before patient enrollment.
The investigator physicians were allowed to use any percutaneous thrombectomy method. The thrombectomy methods that were used in these patients are presented in Table  8 . The distribution of thrombectomy methods was nearly identical for the two treatment groups. The amount of heparin administered during the thrombectomy procedure was left to the discretion of the physician.
Total Procedure Time
The total procedure time was documented for each study patient. The start of the procedure was defined as the moment when the physician gained percutaneous access into the graft. The end of the procedure was defined as the completion of final postprocedural fistulography. The mean procedure times for conventional PTA (n ϭ 167) and PCB treatment (n ϭ 173) were 49.6 minutes and 61.2 minutes, respectively (P ϭ .003).
Pain Assessment
A subjective assessment of procedural pain was performed. The patients were not told which balloon was used to treat their stenosis. Patients were asked if they experienced any pain during balloon inflation and to rate this pain on a five-point ordinal scale with a score of 1 defined as slight pain and a score of 5 defined as severe pain ( Table 9) .
Follow-up
The patient's ability to undergo successful hemodialysis treatment with use of the treated PTFE graft was documented at 14 days, 1 month, 3 months, and 6 months after the treatment procedure. Any graft-related interventions during the 6-month follow-up period were documented. No routine follow-up diagnostic imaging studies were performed.
For patients who presented with a dysfunctional but patent hemodialysis graft, an assessment of the original abnormal clinical parameter (eg, blood flow, venous pressures) was performed and the results were documented. For patients who presented with a thrombosed PTFE graft, the ability to resume normal hemodialysis treatment for at least one session was documented.
Complications
Any complication that occurred during the 6-month follow-up period was documented. The physician investigator was responsible for categorizing the complication and providing a written description on the case report form. All complications were categorized as device-related, procedurerelated, or not related to the device or procedure.
All adverse events were reviewed and adjudicated by an independent clinical events committee. In addition, an independent data safety monitoring board reviewed the safety data throughout the clinical trial to monitor any event or trend that would warrant modification or termination of the trial.
Definitions
Primary Endpoint.-The primary endpoint for this clinical investigation was target lesion primary patency through 6 months. Target lesion primary patency was defined as the time interval between the randomized treatment with PTA or PCB use and the next intervention performed on the target lesion. If the randomized treatment was unsuccessful in treating the target lesion and an adjunctive treatment was necessary, the target lesion primary patency was considered to have failed as of the day of the initial treatment 
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procedure. Abandonment of the treated PTFE graft for any reason constituted the end of primary patency of the target lesion. Secondary Endpoints.-Secondary endpoints included (i) primary patency of the vascular access circuit through 6 months, (ii) procedural success, and (iii) number of repeat interventions in the target lesion. The primary patency of the vascular access circuit was defined as the time interval between the randomized treatment procedure and the next intervention performed on any segment of the circuit. This included interventions to the target lesion, any previously treated secondary lesion, any previously untreated lesions, or any new lesions. Thrombosis or abandonment of the PTFE graft constituted the end of primary patency of the vascular access circuit.
Procedural success was defined as the combination of anatomic success and clinical success. Anatomic success was defined as less than 30% residual stenosis diameter measured immediately after the randomized treatment. Clinical success was defined as an improvement from baseline in the clinical or hemodynamic parameter (eg, blood flow, venous pressures) that was the initial indicator of graft dysfunction. For patients who presented with thrombosed hemodialysis grafts, clinical success was defined as the ability to undergo at least one hemodialysis treatment after the procedure. Study patients who required adjunctive therapy to treat a complication that occurred during the treatment procedure were documented as having received successful treatment if they met the criteria for procedural success.
The third secondary endpoint was the number of repeat interventions performed on the target lesion during the 6-month follow-up period. Any percutaneous or surgical treatment of the target lesion was considered a repeat intervention.
Statistical Analysis
The sample size calculations supported the enrollment of 340 subjects. It was assumed that the 6-month primary patency rate of the conventional PTA group would be approximately 30%. A 20% loss to follow-up was assumed. With a sample size of 340 subjects, a 15% difference in primary patency could be detected with a power of approximately 80%.
Statistical analysis of the primary endpoint and target lesion primary patency was performed on an intentto-treat basis with use of KaplanMeier methodology and further tested with use of the standard log-rank test and Wilcoxon test statistics.
Analysis of secondary endpoints was performed with use of a similar analysis. Vascular access circuit primary patency was determined with use of Kaplan-Meier methodology, standard log-rank test, and Wilcoxon statistics. Procedural success between the two study groups was compared with the Fisher exact test, and the mean number of repeat interventions was compared with use of the Student t test.
Multivariate and univariate modeling analyses were performed to examine covariates as possible predictors for target lesion primary patency and procedural success. All statistical analyses were performed with use of SAS software (SAS Institute, Cary, NC).
RESULTS

Primary Endpoint
The primary endpoint for this clinical investigation was primary patency of the target lesion at 6 months. The initial comparative analysis of this endpoint combined the data from both patient groups, those with stenotic grafts and those with thrombosed grafts. In the 167 patients who underwent conventional PTA, the primary patency rates of the target lesions were 77.7%, 63.4%, and 40.5% at 1 month, 3 months, and 6 months, respectively. In the 173 patients who underwent treatment with the PCB, the target lesion Note.-PTD ϭ percutaneous thrombolytic device. Figure  3 . When comparing PTA with PCB treatment, there was no statistical difference in target lesion primary patency at 6 months (P ϭ .373).
A subgroup analysis was performed to determine if there was a significant difference in target lesion primary patency at 6 months between patients with stenotic grafts and those with thrombosed grafts. For the subgroup of patients who presented with stenotic grafts, the primary patency rate of the target lesion at 6 months in the PTA group was 46.9%, compared with 51.3% for patients who underwent treatment with the PCB (P ϭ .844). For the subgroup of patients who presented with thrombosed grafts, the primary patency rate of the target lesion at 6 months after PTA treatment was 32.0%, compared with 43.1% for patients who underwent treatment with the PCB (P ϭ .150). In summary, the subgroup analysis also demonstrated that there was no statistical difference between the primary patency rates achieved with PTA versus PCB treatment.
Secondary Endpoints
The primary patency of the entire vascular access circuit was considered a secondary endpoint. The initial comparative analysis of this endpoint combined the data from both patient groups, those with stenotic grafts and those with thrombosed grafts. For the group of patients who underwent conventional PTA, the primary patency rates of the vascular access circuits were 75.9%, 61.0%, and 36.3% at 1 month, 3 months, and 6 months, respectively. For the patients who underwent treatment with the PCB, the primary patency rates were 82.6%, 61.0%, and 43.3% at 1 month, 3 months, and 6 months, respectively. A Kaplan-Meier graph of vascular access circuit primary patency is provided in Figure 4 . When comparing PTA versus PCB treatment, there were no statistical differences (P ϭ .531) in the primary patency of the entire vascular access circuit at 6 months.
An analysis of different patient subgroups was also performed. For the subgroup of patients who presented with stenotic grafts and were treated with PTA, the 6-month primary patency rate of the vascular access circuit was 40.9%, compared with 47.3% for patients who underwent treatment with the PCB (P ϭ .756). For the subgroup of patients who presented with thrombosed grafts, the primary patency at 6 months with conventional PTA was 29.3%, compared with 37.5% for patients who underwent treatment with the PCB (P ϭ .237). In summary, when comparing the results achieved with conventional PTA versus those with the PCB, the subgroup analysis failed to demonstrate a statistical difference in the 6-month primary patency rates of the vascular access circuit.
Procedural success was also a secondary endpoint. As previously described, procedural success was defined as a combination of anatomic success and clinical success. Seventyfour patients did not satisfy the criteria for procedural success: 33 patients in the PCB group and 41 in the PTA group. Thirty-three of these procedures failed to achieve anatomic success, 31 procedures did not achieve clinical success, and five procedures did not achieve anatomic or clinical success. For five additional patients in whom procedural success was not achieved, the data report forms did not provide sufficient information to determine the specific reason for failure. Five patients who underwent treatment with the PCB and that did not achieve anatomic success were successfully treated with PTA immediately after the PCB procedure. One patient who underwent conventional PTA that did not achieve anatomic success was then treated with a stent to improve luminal diameter. All study patients, including those in whom the criteria for procedural success were not met, had a functioning hemodialysis graft at the end of the procedure. When comparing conventional PTA versus PCB treatment, there was no statistical difference in the procedural success, anatomic success, or clinical success rates ( Table  10) .
The third secondary endpoint was the number of repeat interventions that were performed on the target lesion during the 6-month follow-up period (Table 11) . When comparing conventional PTA versus PCB treatment, there was no statistical difference in 
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Although the patient's subjective assessment of pain was not a designated secondary endpoint, the results are compelling ( Table 9) . There were more patients that reported "no pain" in the PCB group (67.3%) than in the conventional PTA group (56.3%; P ϭ .034). For those patients who reported pain with balloon inflation, the severity of the pain was significantly less (P ϭ .003) in patients treated with the PCB.
Complications
A summary of the device-related and procedure-related complications is provided in Table 12 . Only one complication (0.6%) occurred in the group of 167 patients who underwent conventional PTA. One patient who presented with a stenotic graft had thrombosis of the vascular access during the treatment procedure. However, as determined by the operating physician, this complication was unrelated to the angioplasty procedure. There were no device-related complications associated with conventional PTA.
There were nine device-related complications involving the group of 173 patients who underwent treatment with the PCB (5.4%). Five patients had venous perforation or rupture, three patients had a venous dissection, and one patient was categorized as having a device-related graft thrombosis. The patients with venous perforation were treated with conventional PTA, stent placement, or both. All but one of these patients was able to undergo hemodialysis treatment after the procedure.
There were 11 additional complication in the PCB group (6.6%) that were categorized as procedure-related but unrelated to the use of the PCB. These additional complications are listed in Table 12 .
DISCUSSION
The PCB was designed to decrease the local vascular trauma caused by conventional balloon angioplasty. In 1991, Barath and colleagues (7) described their experience with use of the cutting balloon in normal porcine arteries. By creating longitudinal incisions into the medial layer of the vascular wall while simultaneously dilating the lesion, the cutting balloon causes less stretching and less injury to the surrounding vascular smooth muscle. These investigators suggested that limiting the extent of angioplastyinduced injury could reduce the expression of proliferative growth factors and thereby decrease the neointimal hyperplasic response (7). This concept was clinically verified by Kondo and colleagues (8) , who used the coronary cutting balloon to treat 127 atherosclerotic lesions in the coronary arteries of 110 patients. In the subgroup of patients who were treated with only the cutting balloon, there was a significant decrease in the degree of restenosis. In addition, the acute gain in luminal diameter was greater when the cutting balloon was used compared with conventional angioplasty.
Vorwerk and colleagues (9) were the first group to report the use of the cutting balloon for treatment of hemodialysis-related venous stenoses. Fifteen patients with 19 venous stenoses underwent treatment with use of 3-mm, 5-mm, and 6-mm cutting balloons. However, 68% of these lesions were also treated with conventional angioplasty balloons during the same procedure. Vorwerk et al (9) achieved a 6-month primary patency rate of 64%, but these results are confounded by the concurrent use of conventional angioplasty. This is a widespread problem that is found in other published reports describing the use of the cutting balloon for treatment of vascular access-related venous stenoses (10 -14) . The results of these studies include patients who underwent concurrent treatment with the cutting balloon and conventional angioplasty. A recent report by Singer-Jordan et al (12) described the use of the cutting balloon as "primary" treatment for fistula-related venous stenoses. However, 40% of the 42 study patients also underwent conventional angioplasty immediately after use of the cutting balloon and two patients received stents. Sreenarasimhaiah et al (14) reported the results of treatment with the cutting balloon in three patients, all of whom also underwent conventional angioplasty and stent placement after use of the cutting balloon. In the majority of these published reports, the cutting balloon was used to treat stenoses that failed to respond to highpressure balloon angioplasty. However, under these circumstances, the long-term patency rate is not necessarily reflective of the cutting balloon. As previously described, the cutting balloon is designed to reduce vascular trauma and thereby reduce neointimal hyperplasia and improve long-term patency of the vascular access. One could theorize that concurrent use of a high-pressure angioplasty balloon would negate these conceptual benefits. This investigation is the first clinical study to prospectively compare the use of the PCB to conventional angioplasty for the treatment of hemodialysis-related venous stenoses. Conventional PTA was not used in patients who were randomized to receive treatment with the PCB. The results of this study are reflective of those achieved with only PCB treatment.
In several respects, this was an exemplary investigation. The patients were enrolled at 27 different medical centers throughout the United States and the procedures were performed by many physicians with different levels of experience. The study was designed as a large, prospective, randomized clinical trial that included patients with dysfunctional stenotic grafts and those with thrombosed grafts. In this respect, the study cohort was reflective of our usual population of patients who require chronic hemodialysis treatment. Statistically, the two patient groups were well-matched for all the parameters under comparison. Important factors such as graft age, characteristics of the target lesion, and number of secondary lesions were nearly identical between patient groups.
In summary, this comparison of PCB treatment versus conventional PTA failed to demonstrate any significant difference in the 6-month patency rate of the target lesion or the entire vascular access circuit. The subgroup analysis also failed to demonstrate any significant differences in the results achieved with use of these two treatment modalities.
The results of this clinical trial should be compared with the expected patency rates described in the nationally recognized standards of reporting documents (6, 15) . The National Kidney Foundation's Dialysis Outcomes Quality Initiative Guidelines for Vascular Access states that, after angioplasty of a stenotic graft, the expected 6-month primary patency rate is 50% (6). Our results did not achieve this value; the 6-month primary patency rates were 47.3% in the PCB group and 40.9% for conventional PTA. However, our results exceeded the 6-month "suggested threshold" patency rate of 40% stated in the Society of Interventional Radiology (SIR) Quality Improvement Guidelines (15) .
When considering the subgroup of 145 patients who presented with thrombosed hemodialysis grafts, the results achieved with use of the PCB exceeded the expected 3-month patency rate of 40% stated in the Dialysis Outcomes Quality Initiative Guidelines. The 6-month primary patency rates were 37.5% for the PCB group and 29.3% for conventional PTA. This improved patency achieved with the use of the PCB in patients with thrombosed grafts is difficult to explain. One could speculate that the PCB is more effective than conventional angioplasty for treatment of severe stenoses associated with thrombosed grafts.
One variable that may have affected the results is the selection of balloon diameter. It is common practice to oversize angioplasty balloons when treating venous anastomotic stenoses. As reported by Arnold et al (16) , the use of an 8-mm-diameter angioplasty balloon can provide substantially better long-term patency compared with a 6-mm-diameter balloon. In patients undergoing treatment with conventional PTA, the physician was allowed to use large-diameter angioplasty balloons. However, the operating physician was restricted from oversizing the diameter of the PCB. The diameter of the PCB had to closely match the diameter of adjacent reference vessel. A review of Table 7 reveals that larger-diameter balloons were used in patients undergoing conventional PTA. One can speculate that this difference in procedural technique may have influenced the outcome in favor of conventional PTA.
This may have also effected other results. Patients who underwent treatment with the PCB reported significantly less pain compared with patients who underwent conventional PTA ( Table 9 ). This may be related to the significantly lower inflation pressures needed for full expansion of the PCB (mean, 8.1 atm Ϯ 1.7) compared with conventional PTA (mean, 15.7 atm Ϯ 4.9; P Ͻ .001). Alternatively, the higher degree of pain may be related to the larger balloon diameters used in patients undergoing conventional PTA. Despite the use of larger balloon diameters, there were no angioplastyrelated complications in the 167 patients who underwent conventional PTA. Although this is certainly a good outcome, it is quite unexpected. The complete absence of complications in such a large group of patients is unusual. In a series of 1,222 hemodialysis graft-related angioplasty procedures, Pappas and Vesely (17) reported an angioplasty-induced venous rupture rate of 2.0%. The SIR Quality Improvement Guidelines for hemodialysis-related interventions specify various threshold complication rates, including 2%-4% for vascular perforation or rupture and 2%-3% for hematoma or bleeding (15) . In the group of 173 patients who were treated with the PCB in the present study, there were eight device-related venous injuries, a complication rate of 4.6%. This is only slightly higher than the SIR threshold values. In addition, the SIR Quality Improvement Guidelines describe two categories of complications: minor complications, which have no significant clinical sequelae; and major complications, which require substantial additional therapy or hospitalization. Seven of the eight patients who had a complication related to the cutting balloon were successfully treated at the time of the initial procedure, and these patients subsequently underwent successful hemodialysis treatment. Therefore, these seven complications are minor complications. However, one patient's hemodialysis graft could not be repaired at the time of the treatment procedure, which represents a major complication.
It should also be noted that, as a result of the short length of the PCB (1 cm), multiple inflations of the balloon were often necessary to treat the entire length of the stenosis. The mean number of balloon inflations was 3.3 for PCB treatment and 1.8 for conventional PTA. This factor may have contributed to the higher complication rate.
The results of this large clinical trial do not provide us with information to define the appropriate use of the PCB. In light of the high cost of this device and its equivalence to conventional angioplasty, it cannot be recommended for the treatment of routine hemodialysis-related venous stenoses. However, as demonstrated by other investigators, it can be a valuable tool for the treatment of lesions in which conventional angioplasty has failed. These include stenoses that fail to respond to dilation with use of highpressure angioplasty balloons and lesions with persistent stenosis (Ͼ30%) after dilation.
In July 2004, the PCB received approval from the United States Food and Drug Administration for use in PTFE hemodialysis grafts. In August 2004, a new version of the PCB with 2-cm-long atherotomes was approved by the Food and Drug Administration. These devices are now used in our daily clinical practice. Continued experience and additional clinical investigation should ultimately determine the most advantageous role for the PCB.
